RIO DE JANEIRO, BRAZIL – Governor João Doria said on Friday, October 2nd, that the state of São Paulo has asked health regulator ANVISA to register for general use the COVID-19 vaccine candidate developed by China’s Sinovac Biotech Ltd, a major step in what could be one of the first vaccination programs in the Americas.
Doria has said he plans to begin inoculating the population of São Paulo with the Sinovac vaccine by mid-December, one of the world’s most aggressive timelines outside China and Russia.
Before he is able to do so, though, he requires approval from ANVISA. Shortly after Doria’s statement, the regulator confirmed it had received the first tranche of data related to the Sinovac vaccine.
São Paulo, Brazil’s most populous state, is one of the sites of Phase III clinical trials for the Sinovac vaccine, now being conducted by the state’s Butantan Institute, a leading biomedical research center.
Last Wednesday, São Paulo signed a US$90 (R$506) million contract to receive 46 million doses of the potential vaccine from Sinovac.
Source: Reuters